Company Profile
KalVista Pharmaceuticals, Inc. Stock Price, News & Catalysts
- Ticker:
- KALV
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
26.95 USD (+0.04%)
Close
Last updated: June 3, 2026
1.43B USD
Market cap
Why the stock is moving
Current closing-price context is not available for KALV.
Company overview
Hereditary Angioedema Company
KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks.
EKTERLY
EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is approved in multiple countries for patients age 12 and older and is commercialized directly or through regional partners.
Pediatric Expansion
The Phase 3 KONFIDENT-KID trial has completed enrollment in children ages 2–11. KalVista plans to use the study to extend oral on-demand treatment to younger patients and pursue additional global filings.
Future catalysts
- U.S. NDA filing for EKTERLY in children ages 2–11 planned for the third quarter of 2026.
- Potential U.S. pediatric launch anticipated in 2027, subject to approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of KalVista Pharmaceuticals, Inc. (KALV)?
KalVista Pharmaceuticals, Inc. (KALV) most recently closed at 26.95 USD, a +0.04% move versus the previous session.
What is the market cap of KalVista Pharmaceuticals, Inc. (KALV)?
KalVista Pharmaceuticals, Inc. currently has a market capitalization of 1.43B USD on BioPharmSignal.
What does KalVista Pharmaceuticals, Inc. do?
Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is approved in multiple...
On which exchange is KALV stock listed?
KalVista Pharmaceuticals, Inc. (KALV) is associated with NASDAQ, United Kingdom, Biopharma.
What is KONFIDENT-KID?
Pediatric Expansion The Phase 3 KONFIDENT-KID trial has completed enrollment in children ages 2–11.
Which conditions is KalVista Pharmaceuticals, Inc. targeting with KONFIDENT-KID?
Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is approved in multiple...
How does KalVista Pharmaceuticals, Inc. describe recent progress with KONFIDENT-KID?
U.S. NDA filing for EKTERLY in children ages 2–11 planned for the third quarter of 2026. Potential U.S. pediatric launch anticipated in 2027, subject to approval.
What is sebetralstat?
EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks.